IDH2 and acute myeloid leukemia: While MRD in IDH-mutated AML has been studied previously, cohort sample size has limited conclusions [6, 38, 39], and large studies examining the significance of IDH2 as a potential AML MRD target are of particular interest due to the possibility of targeted clinical intervention.